• Ming-Ming Tian, Yu-Chen Fan, Jing Zhao, Shuai Gao, Ze-Hua Zhao, Long-Yan Chen, and Kai Wang.
• Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, China.
• Clin Res Hepatol Gastroenterol. 2017 Mar 1; 41 (2): 171-180.

BackgroundLiver cancer ranks as the second leading cause of cancer-related mortality in man worldwide, and hepatocellular carcinoma (HCC) is the most prevalent malignant neoplasm of the liver. The sensitivity of alpha-fetoprotein (AFP) as an HCC diagnostic marker for HCC diagnosis is 39-65%, and one-third patients with HCC are missed using AFP. New biomarkers are needed to diagnose HCC at an earlier stage and to individualize treatment strategies. Hepatocellular carcinoma suppressor 1 (HCCS1) is a newly identified liver tumor suppressor gene.ObjectiveOur study evaluated the diagnostic value of serum HCCS1 promoter methylation in patients with HCC associated with hepatitis B.MethodsWe determined the methylation status of serum HCCS1 promoter in 120 patients with HCC, 146 patients with chronic hepatitis B (CHB) and 27 healthy controls (HCs) by methylation-specific polymerase chain reaction (MSP). Evaluation of a cohort with 63 patients with HCC and 44 patients with CHB was set as a validation dataset.ResultsThe frequency of HCCS1 promoter methylation in patients with HCC was significantly higher than that in patients with CHB (P<0.001) and HCs (P<0.001), and was associated with tumor node-metastasis (TNM) stage (P=0.01). The sensitivity of serum HCCS1 promoter methylation for discriminating patients with HCC from CHB was 62.5% and that of AFP alone was 55%. Notably, the sensitivity of serum HCCS1 promoter methylation plus AFP level was 81.7%.ConclusionHCCS1 has potential as a biomarker for diagnosis and prognosis of patients with HCC.Copyright © 2016 Elsevier Masson SAS. All rights reserved.

36 keywords...

hide…